(Il Sole 24 Ore Radiocor) - Milano, 30 mar - Aurinia Pharmaceuticals said it had agreed to acquire Kezar Life Sciences for 6.955 dollars per share in cash plus potential additional payments.

Aurinia, a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases, said it expected to close the deal in the second quarter.

Kezar is a biotechnology company focusing on small-molecule.

therapeutics to treat unmet needs in autoimmunity and cancer.

(RADIOCOR) 30-03-26 15:28:49 (0395) 5 NNNN